|
1
|
Eom JS, Song WJ, Yoo H, Jeong BH, Lee HY,
Koh WJ, Jeon K and Park HY: Chronic obstructive pulmonary disease
severity is associated with severe pneumonia. Ann Thorac Med.
10:105–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosc C, Clement M, Deroux A, Mammar A,
Pison C and Camara B: Severe pneumonia due to cytomegalovirus in
chronic obstructive pulmonary disease. Rev Mal Respir. 31:435–438.
2014.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giusti M, Blasi F, Iori I, Mazzone A,
Sgambato F, Politi C, Colagrande P, Casali A, Valerio A, Gussoni G,
et al: Prulifloxacin vs Levofloxacin for exacerbation of COPD after
failure of other antibiotics. COPD. 30:1–6. 2016.
|
|
4
|
Dy R and Sethi S: The lung microbiome and
exacerbations of COPD. Curr Opin Pulm Med. 22:196–202. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Z, Bafadhel M, Haldar K, Spivak A,
Mayhew D, Miller BE, Tal-Singer R, Johnston SL, Ramsheh MY, Barer
MR, et al: Lung microbiome dynamics in COPD exacerbations. Eur
Respir J. 47:1082–1092. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Crisafulli E, Torres A, Huerta A, Guerrero
M, Gabarrús A, Gimeno A, Martinez R, Soler N, Fernández L, Wedzicha
JA, et al: Predicting in-hospital treatment failure (≤7 days) in
patients with COPD exacerbation using antibiotics and systemic
steroids. COPD. 13:82–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharan H: Aerobic bacteriological study of
acute exacerbations of chronic obstructive pulmonary disease. J
Clin Diagn Res. 9:DC10–DC12. 2015.PubMed/NCBI
|
|
8
|
Yamaya M: Chronic obstructive pulmonary
disease and severe pneumonia. Geriatr Gerontol Int. 12:177–179.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pettigrew MM, Tsuji BT, Gent JF, Kong Y,
Holden PN, Sethi S and Murphy TF: Haemophilus influenzae in COPD:
Effect of fluoroquinolones and macrolides on eradication and
resistance. Antimicrob Agents Chemother. 2:16–17. 2016.
|
|
10
|
Sethi S, Anzueto A, Miravitlles M, Arvis
P, Alder J, Haverstock D, Trajanovic M and Wilson R: Determinants
of bacteriological outcomes in exacerbations of chronic obstructive
pulmonary disease. Infection. 44:65–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gattarello S, Lagunes L, Vidaur L,
Solé-Violán J, Zaragoza R, Vallés J, Torres A, Sierra R, Sebastian
R and Rello J: Improvement of antibiotic therapy and ICU survival
in severe non-pneumococcal community-acquired pneumonia: A matched
case-control study. Crit Care. 19:3352015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin KY, Wang CC, Lin CH, Sheng WH and
Chang SC: Fluoroquinolones versus β-Lactam/β-Lactamase inhibitors
in outpatients with chronic obstructive pulmonary disease and
pneumonia: A Nationwide Population-Based Study. PLoS One.
10:e01362322015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brill SE, Law M, El-Emir E, Allinson JP,
James P, Maddox V, Donaldson GC, McHugh TD, Cookson WO, Moffatt MF,
et al: Effects of different antibiotic classes on airway bacteria
in stable COPD using culture and molecular techniques: A randomised
controlled trial. Thorax. 70:930–938. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chan KG, Ng KT, Chong TM, Pang YK,
Kamarulzaman A, Yin WF and Tee KK: Antibiotic resistant and
virulence determinants of staphylococcus haemolyticus C10A as
revealed by whole genome sequencing. J Genomics. 3:72–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma X, Cui J, Wang J, Chang Y, Fang Q, Bai
C, Zhou X, Zhou H, Feng H, Wang Y, et al: Multicentre investigation
of pathogenic bacteria and antibiotic resistance genes in Chinese
patients with acute exacerbation of chronic obstructive pulmonary
disease. J Int Med Res. 43:699–710. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hankey B and Riley B: Towards evidence
based emergency medicine: best BETs from the Manchester Royal
Infirmary. BET. 1:use of a procalcitonin algorithm to guide
antimicrobial therapy in COPD exacerbations can reduce antibiotic
consumption with no increase in rates of treatment failure or
mortality. Emerg Med J 32: 493–495. 2015.
|
